Psychedeic-Chronicle-Logo

Suggestions

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS

Psychedeic-Chronicle-Logo

Psychedelic CEO Interviews

Mindset-Pharma-CEO-James-Lanthier-Exclusive-Interview-with-Psychedelic-Chronicle Psychedeic-Chronicle-Logo-White
Psychedelic CEO Interviews

Mindset Pharma CEO James Lanthier Exclusive Interview with Psychedelic Chronicle

August 31, 2022

At Psychedelic Chronicle our team not only delivers the latest news regarding the psychedelic industry ranging from medical research to industry analysis, but we also aim to provide comprehensive coverage of the many facets of this burgeoning field. This includes exclusive interviews and insights

Read More
Mindset-Pharma-CEO-James-Lanthier-Exclusive-Interview-with-Psychedelic-Chronicle Psychedeic-Chronicle-Logo-White
Psychedelic CEO Interviews

Mindset Pharma CEO James Lanthier Exclusive Interview with Psychedelic Chronicle

At Psychedelic Chronicle our team not only delivers the latest news regarding the psychedelic industry ranging from medical research to industry analysis,

August 31, 2022

Recent Posts

  • Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
  • Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
  • atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial
  • Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio
  • Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression

Recent Comments

No comments to show.

Popular

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai has administered the first dosage of their VLS-01 synthetic

Psychedeic-Chronicle-Logo

© 2022 PSYCHEDELIC CHRONICLE
ALL RIGHTS RESERVED.

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS